- Research
- Open Access
- Published:
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
BMC Public Health volume 23, Article number: 859 (2023)
A Correction to this article was published on 18 July 2023
This article has been updated
Abstract
Background
Alcohol related liver disease (ARLD) is one of the major chronic liver diseases worldwide. This review aimed to describe the global prevalence, incidence, and outcomes of ARLD.
Methods
Medline, Embase, The Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched from inception to May 31, 2022. The language was restricted to English or Chinese. According to the criteria, articles describing the basic characteristics of the population were selected. Two reviewers extracted the data independently.
Results
A total of 372 studies were identified: 353 were used for prevalence analysis, 7 were used for incidence analysis, and 114 were used to for outcome analysis. The prevalence of ARLD worldwide was 4.8%. The prevalence in males was 2.9%, which was higher than female (0.5%). Among the ethnic groups, the percentage was highest in Caucasians (68.9%). Alcoholic liver cirrhosis comprised the highest proportion in the disease spectrum of ARLD at 32.9%. The prevalence of ascites in ARLD population was highest (25.1%). The ARLD population who drinking for > 20 years accounted for 54.8%, and the average daily alcohol intake was 146.6 g/d. About 59.5% of ARLD patients were current or former smokers, and 18.7% were complicated with hepatitis virus infection. The incidence was 0.208/1000 person-years. The overall mortality was 23.9%, and the liver-related mortality was 21.6%.
Conclusion
The global prevalence of ARLD was 4.8% and was affected by sex, region, drinking years, and other factors. Therefore, removing the factors causing a high disease prevalence is an urgent requisite.
Trial registration
PROSPERO Nr: CRD42021286192
Background
According to Global Status Report on Alcohol and Health 2018 [1], about 2.3 billion people are drinking alcohol worldwide currently, and more than half of the population in the USA, Europe, and the Western Pacific consumes alcohol. Chronic heavy drinking is the etiology or risk factor for many diseases, such as alcohol related liver diseases (ARLD), acute pancreatitis, and alcohol-related cardiomyopathy [2]. A study showed a 2.1-fold increase in deaths from alcohol poisoning between 2000 and 2019 in USA [3]. According to the WHO data, the global number of deaths caused by alcohol was about 3 million in 2016. Among them, the deaths caused by alcohol-related digestive diseases accounted for 21.3% of all diseases with highest proportion [1]. The total number of deaths was 637,000, including 607,000 cases of ARLD [1]. Therefore, ARLD has become one of the major causes of alcohol-related death.
Due to the popularity of hepatitis B vaccine and the effective application of antiviral therapy worldwide, the status of the HBV as the main cause of the chronic liver disease is declining gradually [4], while alcohol has gained increasing attention. A study [5] showed that the global prevalence of chronic liver diseases due to alcohol use increased by 3.73% between 2005 and 2015. The prevalence of alcoholic liver cirrhosis in cirrhosis population was increased by 43% in 7 years in the USA [6]. The number of deaths from ARLD in South Korea increased from 1403 to 3588 between 2000 and 2009 [7]. These studies suggested that the burden of ARLD is increasing gradually. Therefore, understanding the epidemiology of ARLD is essential to formulate the relevant prevention and control policies.
However, the current epidemiological data on ARLD were obtained from small-scale research. There is no global consensus. In addition to alcohol consumption as a direct factor of liver injury [8, 9], region, gender [10], race, smoking, and other factors have an impact on the prevalence of ARLD. Thus, this meta-analysis described the characteristics of ARLD population in epidemiology, which could help improve the healthcare strategies and reduce the global prevalence of the disease.
Methods
This meta-analysis of observational studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and registered in PROSPERO.
Search strategy and selection criteria
Pubmed, Embase, The Cochrane Library, and CNKI, were searched using the keywords “Liver Diseases, Alcoholic”, “Alcoholic Liver Diseases”, “Alcoholic Liver Disease”, and “Liver Disease, Alcoholic”. The details are described in the Supplementary Table 1. Studies published from the respective inception dates of the databases to May 31, 2022 were eligible for inclusion in this meta-analysis. The language of the literature was limited to English or Chinese.
Data extraction and quality assessment
Two reviewers searched the studies and extracted the data independently. Any disagreements on the eligible studies and data extraction were resolved by consensus and/or discussion with a third author. The included literature is listed in the Supplementary Tables 2, 3, 4 and 5. Newcastle–Ottawa scale was used to evaluate the quality of the studies, ranging from 0–9: 7–9 represented a high-quality score, 4–6 represented a medium score, and 1–3 represented a low score. Studies with scores < 4 were excluded.
Study definitions
ARLD is a series of liver injuries caused by long-term high-alcohol intake, including mild alcoholic liver disease, alcoholic fatty liver disease, alcoholic hepatitis, alcoholic cirrhosis, and related complications [11]. ARLD was diagnosed according to long-term drinking history or short-term heavy drinking history, without autoimmune hepatitis, drug-induced liver diseases, or other genetic disorder related liver diseases. It should be evaluated though blood biochemical testing, ultrasound, transient elasticity, CT, MRI, and biopsy [12, 13]. The concrete situation was determined based on the latest diagnostic criteria of the corresponding year. The general population without defined diseases was referred to the physical examination at the health care center and participated in the epidemiological survey. Original research articles that defined their population as ARLD and/or general population were included. Including studies should also provide the data on the prevalence, incidence and outcomes of ARLD. Study designs with unrestricted types were eligible for inclusion. In case of duplicate data, the largest and latest datasets were selected. Articles were excluded if the diagnosis of ARLD were unclear; the number of participations were < 50 in the baseline; age < 18-years-old; the study population was limited to either one gender; specific groups with other chronic diseases, such as non-alcoholic liver disease, drug-induced liver disease, and acquired immune deficiency syndrome.
Data analysis
The incidence of ARLD was studied in the general population at baseline without the disease. To estimate the incidence, we used the number of new cases and the follow-up time (person-years). The baseline characteristics of ARLD population, including prevalence, mortality, and cause of death, were described. In order to study the influencing factors of prevalence, we analyzed region, sex, race, disease severity, complications, drinking years, smoking, virus infection, and other factors. Moreover, the global prevalence was compared between 2000–2010 and 2011–2021.
Statistical analysis
Cochran Q and I2 statistics were used to assess the heterogeneity. p-value < 0.05 in Q-statistic and I2 ≥ 50% were considered moderate or severe heterogeneity. Due to the heterogeneity of global data, random-effects model was applied to analyze each study dataset. Funnel plot and Egger’s test (the figures of main result are listed in Supplementary Figs. 1– 5) were used to evaluate the publication bias. All statistical analyses were conducted using Meta package in Stata statistical software.
Results
Study selection and characteristics
According to the above-defined search terms in methods, 64,321 studies were retrieved, and 368 studies were included according to the inclusion criteria. While searching for relevant articles, four additional studies were added. Finally, 372 articles were included: 353 studies for prevalence analysis, 7 for incidence analysis, and 114 for outcome analysis (some studies provided data on prevalence, incidence and/or outcomes at the same time; hence, the total number was different from the sum of subgroups) (Fig. 1).
Study selection. The entire screening process were described, including the selected the reasons for the exclusion of articles and the number of including and excluding artcles. ARLD: alcohol-associated liver disease. HBV: hepatitis B virus. HCV: hepatitis C virus. HIV: human immunodeficiency virus. DILI: drug-induced liver injury.* Some articles were used for more than one of the analyses of prevalence, incidence, and outcomes. # When searching for relevant articles found 4 additional articles that met the inclusion criteria
Prevalence of ARLD
The overall prevalence of ARLD in general population was 4.8% [95% confidence interval (CI): 4.1–5.6] (99 studies, 198,423,289 participations) (Table 1). The prevalence fluctuated from 1.0 to 16.1% and higher in male compared to female (2.9% vs. 0.5%, p < 0.001).
By geographic region and province
The information on the prevalence of ARLD in different countries and regions is summarized in Table 1 and Figs. 2 and 3. The study encompassed 14 countries, including Portugal [14], Canada [15], Iceland [16], France [17, 18], China (see the following paragraph), USA [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35], Denmark [36,37,38], South Korea [39, 40], Uganda [41], India [42, 43], UK [10, 44,45,46,47], Sweden [48], Japan [49,50,51,52,53,54], and Italy [55,56,57](Fig. 2 and Table 1). The global prevalence of ARLD in general population was 4.8% (95% CI: 4.1–5.6) (Fig. 2), which we got from 99 datasets. As the region with the highest alcohol consumption in the world [12], Europe had the highest prevalence (5.4%, 95% CI: 3.9–7.1). According to the analysis results in Table 1 and the color depth distribution in Fig. 2, the prevalence of ARLD was higher in most European countries. Italy had the highest prevalence rate of 16.1% (95% CI: 1.2–43.3), followed by Sweden (14.0%, 95% CI: 13.0–15.0) and the UK (7.2%, 95% CI: 3.0–13.0), while France, Denmark, Iceland and Portugal had the lowest prevalence rates: 1.4% (95% CI: 1.3–1.4), 1.2%(95% CI: 0.1–3.4), 1.0% (95% CI: 0.8–1.2) and 1.0% (95% CI: 0.9–1.1), respectively (Table 1, Fig. 2). Although alcohol consumption in Asia was less than that in Europe, the prevalence in India (11.8%, 95% CI: 10.7–12.9) and Japan (10.4%, 95% CI: 3.2–20.9) was high (Table 1). Uganda in Africa has the high prevalence of 11.0% (95% CI: 7.7–10.2). Surprisingly, the United States, with the largest number of studies (17 studies) and participants (137,929,285 persons), had the lower prevalence (5.0%, 95% CI: 2.9–7.6) (Table 1).
The global prevalence of ARLD. The prevalence in 14 countries was indicated by depth of red. The 14 countries included Portugal, Canada, Iceland, France, China, USA, Denmark, South Korea, Uganda, India, UK, Sweden, Japan, and Italy
The prevalence of ARLD in China by provinces. The prevalence in 21 provinces of China was indicated by depth of red. The prevalence in China was obtained from the analysis of 21 cities or provinces including Sichuan, Beijing, Guangdong, Jiangsu, Shanghai, Gansu, Shaanxi, Guizhou, Zhejiang, Henan, Hunan, Jilin, Heilongjiang, Taiwan, Tibet, Liaoning, Yunnan, Anhui, Shandong, Hebei, and Xinjiang provinces
Since the pathogenesis of ARLD in Western countries, which has been well-documented, differed from that in China [9], the prevalence in China’s provinces was analyzed separately. The prevalence of ARLD was 3.9% (95% CI: 2.9–5.1) (Table 1) in Chinese people, which was lower than the global prevalence. Data from 21 cities or provinces, including Sichuan [58,59,60,61,62], Beijing [63,64,65,66], Guangdong [67,68,69,70,71], Jiangsu [72, 73], Shanghai [74, 75], Gansu [76, 77], Shaanxi [78,79,80], Guizhou [81, 82], Zhejiang [83,84,85,86,87,88,89], Henan [90, 91], Hunan [92, 93], Jilin [94,95,96,97], Heilongjiang [98], Taiwan [99], Tibet [100], Liaoning [101], Yunnan [102, 103], Anhui [104, 105], Shandong [106, 107], Hebei [108], and Xinjiang [109] provinces, were collected (Fig. 3 and Table 1). The prevalence in Xinjiang was 10.7% (95% CI: 9.5–11.9), which was much higher than the overall prevalence in China. It was the province with the highest prevalence, followed by Hebei (9.8%, 95% CI: 7.9–12.0) and Shandong provinces (8.1%, 95% CI 7.5–8.7), which were famous for strong drinking. Surprisingly, Shaanxi and Gansu provinces, famous for binge drinking, had the lower prevalence. Further analysis of Northeast China [95,96,97,98, 101] (including Heilong, Jilin, and Liaoning provinces) and Northwest China [76,77,78,79,80, 109,110,111] (including Xinjiang, Shaanxi, and Gansu provinces) showed that the prevalence was 4.8% (95% CI: 3.7–6.0) and 5.9% (95% CI: 4.2–7.9), which were much higher than the national prevalence. The prevalence rates were relatively low in Sichuan (1.8%, 95% CI: 1.1–2.6), Beijing (1.9%, 95% CI: 0.1–5.5), Guangdong (1.9%, 95% CI: 0.7–3.6), Jiangsu (2.2%, 95% CI: 1.9–2.5), and Shanghai (2.9%, 95% CI: 2.5–3.3), all which were relatively economically developed regions (Table 1).
By sex
Herein, 58 studies [14,15,16, 18,19,20, 22,23,24,25, 29,30,31, 33,34,35,36,37,38,39,40, 44,45,46, 50, 53, 55, 56, 58,59,60, 63,64,65,66,67, 71, 77, 78, 80, 81, 84,85,86, 92, 93, 96, 97, 99,100,101, 104,105,106,107, 111] were included to analyze the influence of sex on the prevalence of ARLD. The prevalence of male was 2.9% (95% CI: 2.4–3.5), which was much higher than that of women (0.5%, 95% CI: 0.4–0.7) (Table 1).
By study period
In order to further analyze the changes in the global ARLD prevalence in different periods, seventy three articles indicating the study years were included. From these, 48 articles [10, 20, 25, 26, 30, 34, 35, 37, 40, 42,43,44, 48, 50, 53, 59,60,61,62,63, 67,68,69, 71,72,73,74, 76, 80, 81, 83, 85, 87,88,89,90,91, 93,94,95,96,97, 99,100,101,102, 109, 111] were used for subgroup analysis of the prevalence from 2000 to 2010: 4.6% (95% CI: 4.2–5.1) (Table 1). A total of 18 articles [10, 17, 19, 22, 26, 41, 43, 49, 51, 52, 65, 70, 75, 78, 79, 82, 104, 106] were used to analyze the prevalence in 2011–2021, and the result was 5.6% (95% CI: 2.4–10.1), which was significantly higher in this period than in 2000–2010 (Table 1).
The characteristic of ARLD
The characteristics of ARLD patients in nationality, race, disease severity, complication, drinking years, smoking/smoked, and hepatitis virus infection are different. This part was described by comparing the percentage of each part of ARLD population.
By race and nationality
For race, categories included Caucasians, Africans, Hispanic and Asians, and these are the relatively lager amount of data that we can gather from the studies. According to the 46 articles [20,21,22,23,24,25,26, 29,30,31, 33, 35, 112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145] collected, the proportion of Caucasians was the highest (68.9%, 95% CI: 67.6–70.2) in ARLD, which was much higher than Africans (8.9%, 95% CI: 8.5–9.4) and Hispanic (8.6%, 95% CI: 7.9–9.4) (Table 2). The Asians was the lowest (0.3%, 95 CI: 0.1–0.6), with wide variation between races.
China has multiple ethnic groups. The data [103, 146,147,148,149,150,151,152,153,154] collected in this study divided Chinese people with ARLD into Han nationality and other minorities, which including Mongol, Chosen, Li, Hmong, Kazak, Uyghurs, Xibe, Hani, Yi and Dai (Table 2). The minority group accounted for 61.6% (95% CI: 52.8–70.0), which was much higher than in the Han group (38.4%, 95% CI: 30.0–47.2).
By duration of alcohol intake and the daily dose of pure alcohol consumption
Alcohol as a pathogenic factor, drinking years and average daily drinking consumption affected the natural course of ARLD. According to the data of ARLD population, they were divided into three subgroups with drinking years of 5–9, 10–19, > 20. The ARLD with drinking duration > 20 years accounted for 54.8% (95% CI: 46.9–62.6) (Table 2). The analysis of the 19 studies [78, 80, 81, 84, 92, 95, 146, 148, 149, 151, 155,156,157,158,159,160,161,162,163] describing the correlation between drinking years and ARLD revealed that the longer the drinking years, the more patients with ARLD. The average daily alcohol consumption of 4184 ARLD patients [98, 133, 140, 153, 164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179] included in the study was up to 146.6 g/d (95% CI: 123.8–169.4) (Table 2), which was much higher than the excessive drinking defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA): > 4 cups/day for men and > 3 cups/day for women (1 standard cup = 14 g alcohol) [180].
By smoking and hepatitis viral infectious
As a risk factor of many diseases, tobacco has been proven to increase the risk of liver fibrosis [181]. Among 27 articles [19, 23, 24, 33, 37, 40, 49, 163, 171,172,173, 179, 182,183,184,185,186,187,188,189,190,191,192,193,194,195,196], 106,599 people were diagnosed with ARLD, of which 53,661 were former or current smokers, accounting for 59.5% (95% CI: 55.9–63.1) (Table 2). Three articles [37, 186, 188] described that smoking promoted disease progression, and two studies [23, 33] showed that smoking increased the mortality and hospitalization rates. In addition to advising the patients to quit alcohol, education on smoking cessation was also conducive to improving the progress of ARLD.
Hepatitis virus infection and alcohol are the major causes of chronic liver disease. Among the 67 articles [19, 21, 25, 26, 30, 40, 53, 87, 99, 114, 115, 120, 121, 123, 125, 126, 156, 158, 161, 167, 168, 171, 172, 176, 192, 194, 196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236] included, 92,548/1473951 patients with ARLD were complicated with a hepatitis viral infection, with the prevalence of 18.7% (95% CI: 16.0–21.5), and the infection rate of HCV (5.6%, 95% CI: 4.1–7.4) was higher than that of HBV (3.6%, 95% CI: 3.0–4.3) (Table 2). Three of the 67 articles [210, 235, 236] described that the liver damage caused by concurrent hepatitis virus infection and alcohol was severe. One article [194] suggested that the presence of both causes an increased possibility of 30-day readmission. The data of 4 studies [30, 126, 201, 204] showed that the mortality of ARLD with virus infection was higher than that of ARLD only. Therefore, antiviral drugs are essential for ARLD with hepatitis viral infection while abstaining from alcohol.
By the stage of disease and complications
ARLD caused by long-term heavy drinking included the whole disease spectrum from liver steatosis to liver cirrhosis and even liver cancer [237]. The constituent ratio of alcoholic cirrhosis in ARLD population was the highest, up to 32.9% (95% CI: 27.3–38.7) (Table 2) got from 147 articles [16, 19, 25,26,27, 31, 36, 46, 64, 66, 80, 81, 84, 86, 91, 92, 98, 100,101,102, 111, 113, 117, 119, 121,122,123,124, 145, 148, 149, 152, 153, 157, 159,160,161,162, 165, 170, 173,174,175,176, 187, 193, 194, 197, 199, 208, 219, 221,222,223, 225, 227, 229,230,231,232,233,234, 236, 238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321]. A total of 119 datasets [25, 26, 30, 43, 47, 113, 115, 116, 122, 125, 126, 128, 129, 131, 132, 136, 137, 142, 153, 156, 157, 161, 162, 168, 171,172,173, 176, 178, 186, 190, 193,194,195,196,197, 204, 207, 208, 213, 215, 221, 225,226,227,228,229,230, 241,242,243, 245, 250,251,252, 255, 262, 267, 272, 275, 276, 294, 297, 299, 306, 311, 318, 321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372] were used to analyze the prevalence of ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous peritonitis (SBP), hepatorenal syndrome, and bacterial infection in ARLD. Ascites were the most common complication, with a prevalence of 25.1% (95% CI: 20.5–30.0), three times that of gastrointestinal bleeding (Table 2).
SBP is the most common and life-threatening bacterial infection in cirrhotic patients with ascites. The prevalence of SBP in ARLD population was not high (0.2%, 95% CI: 0–0.5) (Table 2). However, the prevalence of SBP in alcoholic cirrhosis [25, 122, 132, 194, 204, 208, 356, 362, 368, 373] with ascites was 12.5% (95% CI: 10.7–14.4). Since the clinical symptoms of SBP were often occult and only limited research data were available, the prevalence may be underestimated. The occurrence of the above complications often indicated decompensated alcoholic cirrhosis, which was the predictor of mortality. Diabetes is also one of the critical factors affecting prognosis. A total of 40 studies [26, 33, 77, 131, 145, 156, 159, 171, 172, 176, 178, 183, 207, 215, 220, 221, 223, 226, 228, 260, 270, 294, 295, 297, 306, 307, 348, 360, 368, 372, 374,375,376,377,378,379,380,381,382,383] showed that 15.6% (95% CI: 12.8–18.7) ARLD were complicated by diabetes.
Incidence of ARLD
To estimate the incidence of ARLD, data from 7 eligible cohort studies [16, 39, 47, 384,385,386,387] were selected, with a cumulative follow-up of 368,565,116.7 person-years. The number of newly defined ARLD cases was 62,819, and the incidence was 0.208 (95% CI: 0.125–0.305) per 1000 person-years (Table 3). The incidence in males was about four times as high as that in females (0.163 vs. 0.035 per 1000 person-years, p < 0.05) (Table 3), suggesting a significant gender difference in the incidence.
Mortality and cause of ARLD death
A total of 114 datasets [17, 23, 25, 26, 30, 33, 36, 39, 43, 46, 64, 115, 126, 128, 130, 136, 140, 142, 156, 162, 168, 169, 173, 176, 186, 189, 190, 192, 196, 197, 204, 208, 213, 216, 220, 223, 225, 228, 231, 236, 242,243,244,245, 249, 258, 265, 267, 273, 276, 280, 283, 294, 307, 309, 311, 320,321,322, 324,325,326,327,328,329, 332,333,334,335,336, 338,339,340,341,342,343,344,345, 347, 348, 353, 355, 356, 359, 364, 366,367,368,369,370,371,372,373,374,375, 380, 382, 385, 386, 388,389,390,391,392,393,394,395,396,397,398,399,400,401,402] were used to analyze the mortality, including 786,199 ARLD patients, while 183,929 people died during the study (Table 4). The mortality was 23.9% (95% CI: 18.9–29.2). Since not all studies provided the analysis of the causes of death, 22 articles [33, 46, 47, 162, 168, 189, 243, 245, 249, 265, 273, 326, 338, 340, 344, 345, 356, 364, 378, 390, 396, 401] were selected for subsequent analysis, with the mortality of 37.1% (95% CI: 27.7–47.1). According to the funnel plot and Egger’s test, p = 0.612 indicated that the funnel plot was symmetrical, i.e., no publication bias in the 22 datasets. A total of 15,965 individuals suffered from ARLD, of which 4746 died of liver disease and related complications. The mortality related to liver diseases was 21.6% (95% CI: 15.8–28.1), about twice that of non-liver diseases (10.4%, 95%CI: 6.3–15.3) (Table 4).
Discussion
ARLD is a common chronic liver disease caused by long-term heavy drinking. Alcoholic fatty liver could develop into alcoholic hepatitis characterized by inflammation, which further progresses to alcoholic liver fibrosis, alcoholic cirrhosis, and even cancer in some cases. The whole process is affected by the interaction of many risk factors involved in this article, such as sex, race, hepatitis virus infection and smoking. Genetic and other potential etiology of liver diseases which identified in this article could also affect the natural course of the disease. The co-existence of multiple risk factors could largely promote the progression of ARLD through complex molecular mechanisms. Several studies have shown that alcohol abuse is accompanied by metabolic syndrome [252, 403] or hepatitis virus infection [404, 405], would accelerate the speed of liver fibrosis. Another study demonstrated that 70% of HCV-infected patients in Europe and North America are heavy drinkers [406], which is in agreement with the high prevalence shown in the present study.
According to the 2018 National Survey on Drug Use and Health, 14.4 million adults ≥ 18-years-old suffered from alcohol use disorders in the United States, including 9.2 million men and 5.3 million women [407]. Since 2000, men have been drinking about three times as much as women, according to the latest WHO data [408]. The current data also showed that the prevalence of ARLD in male was 2.9% which was nearly six times that in female, which could be related to the socioeconomic status and alcohol consumption level of men and women. Although the prevalence of different sexes varied greatly, women’s susceptibility to alcohol cannot be ignored. According to the WHO statistics, the global alcohol consumption is increasing [1], with the average level of alcohol consumption in 2005 was 5.5 L of pure alcohol per capita, and in 2016 was 6.1L [1, 408]. The current findings showed that the prevalence during 2011–2021 was higher than that during 2000–2010, which was consistent with the epidemiological characteristics of alcohol.
Significant differences in alcohol consumption patterns, metabolism, genetics, and socio-economic factors among different subgroups affected the prevalence of ARLD. A direct correlation was established between alcohol and liver disease. The longer the drinking years and/or the higher the average daily drinking amount, the higher the risk of ARLD. Therefore, the distribution of high prevalence rates was consistent with regions where drinking culture was in vogue. Although Europe is still the region with the highest prevalence in the world, Portugal and France are the lowest which have a long history of wine. Thus, it could be deduced that the type of alcohol may also have an impact on the prevalence. Askgaard et al. demonstrated that red wine had a lower risk than other types of alcoholic beverages when drinking the same amount of alcohol [384]. In Uganda, the prevalence of homemade alcoholic beverages is high [409]. Similar issues may be seen in some provinces in China, such as Xinjiang, Hunan and Henan provinces [410]. This phenomenon may be also related to the cultural customs of different ethnic groups. Many minorities had the tradition of homemade alcoholic beverages. For example, Duihua wine, the special homemade wine unique to the Dai nationality, has a high alcohol content of over 60%. Its health risk may also be attributed to its toxic impurities, such as heavy metals and acetaldehyde [411]. The prevalence in USA which is lower than our expectations may be attributed to the government restriction on alcohol consumption. The United States established NIAAA in 1971 [412], and has a stable government funding program. For example, the raised alcohol taxes and the restriction of the time and place of alcohol sales have significantly reduced the incidence of ARLD. The comparison of prevalence in different countries reflected the advantages, which could be used as a reference for countries with a high prevalence. With the improvement of the economic level of developing countries, the prevalence in Asia is raising, which should be paid more attention. Base on the WHO data, the total per capita alcohol consumption in India increased from 2.4L in 2005 to 5.7L in 2016, while the per capita alcohol consumption in China increased from 4.1L in 2005 to 7.2L in 2016 [1]. Although the alcohol consumption in India was lower than that in China, the prevalence in India was significantly higher than that in China, which was related to socio-economic factors.
Smoking is an independent risk factor for liver fibrosis that could accelerate the natural course of ARLD [181]. Whether a dose-related correlation was established between tobacco and the disease and whether the progression of ARLD was related to smoking years needs to be confirmed further by a large number of studies. Based on the current results, > 50% of ARLD had former or current smoking. The harmful effect of smoking on liver-related diseases should be under intensive focus. Hepatitis virus infection and alcohol are the main pathogenic factors of chronic liver injury; their co-existence could aggravate liver damage through virus replication and immune suppression [406, 413]. Therefore, treating the co-existent viral hepatitis with antiviral drugs is imperative.
Some studies proposed that moderate drinking was beneficial to health [414,415,416], but the defined alcohol intake and types of alcohol have not reached a consensus. American Association for the Study of Liver Diseases has set a safe threshold of alcohol consumption for men (no more than 2standard drinks per 24 h) and women (no more than 1standard drinks per 24 h) [417]. Meanwhile, the research results have shown that the longer the drinking years, the more patients suffer from ARLD. Early abstinence from alcohol is crucial to reducing the risk of ARLD.
While analyzing the influence of race on ARLD, we found that the proportion varies greatly among different subgroups, especially Caucasians and Asians. Notably, the percentage of the minority group with ARLD was much higher than the Han group. This phenomenon could be attributed to the difference in the constitution and the cultural customs; whether we could improve the early detection rate by setting different safety thresholds for different ethnicities needs to be investigated further.
The advantages of this study were to provide as complete as possible the epidemiological characteristics of ARLD. Presently, the epidemiological investigations of ARLD are mainly regional studies. This study provided the necessary data for countries to study ARLD and provided the trend of the disease to help the government in formulating alcohol management policies and conducting public education. Nevertheless, the present study had some limitations: the high heterogeneity between each study, which is common in such meta-analysis; only 1 or 2 datasets were included in subgroups resulting in the limitations of the results.
The eight studies to calculate the incidence are mainly concentrated in Europe, where the alcoholic population is concentrated, so the results are relatively high. Large cohort study, which cost a lot of manpower and material resources, is very important to explore the global incidence. Based on the premise of large population base and long follow-up time, the results of this review can reflect the global incidence to a certain extent. The phenomenon—mortality deduced from the 22 datasets was used to analyze the cause of death, which was much higher than that of 114 studies used for the analysis of mortality. This phenomenon could be attributed to the following reasons: the populations in the articles providing the cause of death were serious; the sample size was small; the study population was concentrated in European countries. Therefore, 23.9% was similar to the level of global mortality.
Taken together, these results showed that ARLD is one of the most common chronic liver diseases in the world, with a prevalence of 4.8%. With an improved economy, the per capita alcohol consumption is increasing rapidly, and the increasing risk of ARLD in developing countries is gaining much attraction. In addition to strengthening the management of abstinence from alcohol, we should investigate the metabolism, histology, and clinical characteristics of ARLD. Also, we should get rid of the dependence on asking the patients about their drinking history for diagnosis. Thus, non-invasive examinations and specific biomarkers are essential for early recognition. In addition to banning alcohol intake, developing safe and effective intervention measures, such as using the gut-liver axis with probiotics and prebiotics to improve the gut microbiota. Nonetheless, there are still many issues with respect to the prevention, development, and prognosis of ARLD that need to be investigated to improve the epidemiology of ARLD.
Conclusions
Overall, the global prevalence of ARLD is 4.8%, and the prevalence varies greatly among different regions, which may be influenced by various factors such as gender, race/ethnicity, drinking years, comorbidities and so on. With the improvement of economic level, the prevalence of ARLD is on the rise. By increasing alcoholic taxes and controlling the quantity and timing of alcohol sales, the harm caused by alcohol can be reduced to some extent. Large—scale cross-sectional and cohort studies are helpful to understand the epidemiological characteristics of ARLD.
Availability of data and materials
The data that support the findings of this study are available from the corresponding author.
Change history
18 July 2023
A Correction to this paper has been published: https://doi.org/10.1186/s12889-023-15986-0
Abbreviations
- ARLD:
-
Alcohol related liver disease
- CNKI:
-
China National Knowledge Infrastructure
- NIAAA:
-
National Institute on Alcohol Abuse and Alcoholism
- SBP:
-
Spontaneous peritonitis
References
Global status report on alcohol and health 2018 [https://www.who.int/substance_abuse/publications/global_alcohol_report].
Ding C, O’Neill D, Bell S, Stamatakis E, Britton A. Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women. BMC Med. 2021;19(1):167.
Buckley C, Ye Y, Kerr WC, Mulia N, Puka K, Rehm J, Probst C. Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment, and race and ethnicity for the United States 2000–2019. BMC Med. 2022;20(1):405.
Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71(1):212–21.
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602.
Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, Blow FC, Lok ASF. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology (Baltimore, MD). 2018;68(3):872–82.
Bang HA, Kwon YH, Lee MJ, Lee WC. Trends in the epidemiological aspects and mortality of alcoholic liver disease in Korea in the decade between 2000 and 2009. J Clin Med Res. 2015;7(2):91–6.
Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160–8.
Im PK, Millwood IY, Kartsonaki C, Guo Y, Chen Y, Turnbull I, Yu C, Du H, Pei P, Lv J, et al. Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: a 10-year prospective study of 0.5 million adults. BMC Med. 2021;19(1):216.
Green MA, Strong M, Conway L, Maheswaran R. Trends in alcohol-related admissions to hospital by age, sex and socioeconomic deprivation in England, 2002/03 to 2013/14. BMC Public Health. 2017;17(1):412.
Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175–94.
Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.
Association NWoFLaALDCSoHCM, Association FLECCMD. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update. 2018.
Cortez-Pinto H, Marques-Vidal P, Monteiro E. Liver disease-related admissions in Portugal: clinical and demographic pattern. Eur J Gastroenterol Hepatol. 2004;16(9):873–7.
Slaunwhite AK, Macdonald S. Primary health care utilization for alcohol-attributed diseases in British Columbia Canada 2001–2011. BMC Fam Pract. 2015;16(1):34.
Hauksson K, Arnardottir M, Agustsson AS, Magnusdottir BA, Baldursdottir MB, Lund SH, Kalaitzakis E, Bjornsson ES. Increase in the incidence of alcoholic pancreatitis and alcoholic liver disease in Iceland: impact of per capita alcohol consumption. Scand J Gastroenterol. 2020;55(5):615–20.
Mallet V, Beeker N, Bouam S, Sogni P, Pol S. Demosthenes research g: Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020. J Hepatol. 2021;75(4):848–55.
Duchmann JC, Joly JP, Decrombecque C, Delcenserie R, Levy S, Capron D, Capron JP. Cirrhosis: a new, but expected cause of biliary sludge. Alcohol Clin Exp Res. 1997;21(1):119–21.
Adejumo AC, Ajayi TO, Adegbala OM, Adejumo KL, Alliu S, Akinjero AM, Onyeakusi NE, Ojelabi O, Bukong TN. Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease. Liver Int. 2018;38(8):1475–86.
Cuthbert JA, Arslanlar S, Yepuri J, Montrose M, Ahn CW, Shah JP. Predicting short-term mortality and long-term survival for hospitalized US patients with alcoholic hepatitis. Dig Dis Sci. 2014;59(7):1594–602.
Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic Liver Disease Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. Am J Gastroenterol. 2020;115(1):96–104.
Gonzalez HC, Zhou Y, Nimri FM, Rupp LB, Trudeau S, Gordon SC. Alcohol-related hepatitis admissions increased 50% in the first months of the COVID-19 pandemic in the USA. Liver Int. 2022;42(4):762–4.
Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136(10):1248–57.
Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166(11):1190–5.
Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9.
Nguyen TA, DeShazo JP, Thacker LR, Puri P, Sanyal AJ. The Worsening Profile of Alcoholic Hepatitis in the United States. Alcohol Clin Exp Res. 2016;40(6):1295–303.
Piette JD, Barnett PG, Moos RH. First-time admissions with alcohol-related medical problems: a 10-year follow-up of a national sample of alcoholic patients. J Stud Alcohol. 1998;59(1):89–96.
Singal AK, Arora S, Wong RJ, Satapathy SK, Shah VH, Kuo YF, Kamath PS. Increasing burden of acute-on-chronic liver failure among alcohol-associated liver disease in the young population in the United States. Am J Gastroenterol. 2020;115(1):88–95.
Singal AK, Arsalan A, Dunn W, Arab JP, Wong RJ, Kuo YF, Kamath PS, Shah VH. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther. 2021;54(4):451–61.
Singal AK, Kuo YF, Anand BS. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol. 2012;24(10):1178–84.
Tao N, Sussman S, Nieto J, Tsukamoto H, Yuan JM. Demographic characteristics of hospitalized patients with alcoholic liver disease and pancreatitis in los angeles county. Alcohol Clin Exp Res. 2003;27(11):1798–804.
Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016;14(8):1181-1188 e1182.
Trimble G, Zheng L, Mishra A, Kalwaney S, Mir HM, Younossi ZM. Mortality associated with alcohol-related liver disease. Aliment Pharmacol Ther. 2013;38(6):596–602.
Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001–2016. JAMA. 2019;321(17):1723–5.
Jinjuvadia R, Liangpunsakul S. Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States. J Clin Gastroenterol. 2015;49(6):506–11.
Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology (Baltimore, MD). 1996;23(5):1025–9.
Dam MK, Flensborg-Madsen T, Eliasen M, Becker U, Tolstrup JS. Smoking and risk of liver cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2013;48(5):585–91.
Jepsen P, Lash TL, Vilstrup H. The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study. Liver Int. 2016;36(11):1696–703.
Lee JY, Cho Y, Hong MH, Kim J, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: a nationwide study. J Gastroenterol Hepatol. 2019;34(4):747–54.
Park SH, Kim CH, Kim DJ, Park JH, Kim TO, Yang SY, Moon YS, Kim TN, Kim HK, Park HY, et al. Prevalence of alcoholic liver disease among Korean adults: results from the fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse. 2011;46(14):1755–62.
O’Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, Asiki G, Seeley J, Matthews PC, Newton R. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open. 2020;10(3):e032890.
Garg R, Aggarwal S, Singh H, Kajal KS, Garg R, Pal R. Study of the relation of clinical and demographic factors with morbidity in a tertiary care teaching hospital in India. Int J Crit Illn Inj Sci. 2013;3(1):12–7.
Ray G. Trends of chronic liver disease in a tertiary care referral hospital in Eastern India. Indian J Public Health. 2014;58(3):186–94.
Hislop WS, Heading RC. Caledonian Society of G: Impact of alcohol related disease and inpatient workload of gastroenterologists in Scotland. Scott Med J. 2004;49(2):57–60.
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Collier J. Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J Gastroenterol Hepatol. 2008;20(5):384–92.
Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut. 2005;54(11):1615–21.
Saunders JBWJ, Davies AP, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed). 1981;282(6266):819.
Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol. 2019;54(8):1027–32.
Hamaguchi M, Obora A, Okamura T, Hashimoto Y, Kojima T, Fukui M. Changes in metabolic complications in patients with alcoholic fatty liver disease monitored over two decades: NAGALA study. BMJ Open Gastroenterol. 2020;7(1):1–8.
Horie Y, Yamagishi Y, Ebinuma H, Hibi T. Obesity, type 2 diabetes, age, and female gender: significant risk factors in the development of alcoholic liver cirrhosis. Hepatol Int. 2013;7(1):280–5.
Iritani S, Kawamura Y, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, et al. The useful predictors of zinc deficiency for the management of chronic liver disease. J Gastroenterol. 2022;57(4):322–32.
Nishikawa H, Shiraki M, Hiramatsu A, Hara N, Moriya K, Hino K, Koike K. Reduced handgrip strength predicts poorer survival in chronic liver diseases: a large multicenter study in Japan. Hepatol Res. 2021;51(9):957–67.
Ozaki K, Matsui O, Gabata T, Kobayashi S, Koda W, Minami T. Confluent hepatic fibrosis in liver cirrhosis: possible relation with middle hepatic venous drainage. Jpn J Radiol. 2013;31(8):530–7.
Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2020;55(3):353–62.
Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Dionysos Study Group Gut. 1997;41(6):845–50.
Capocaccia L. Nutritional status in cirrhosis. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. J Hepatol. 1994;21(3):317–25.
Stroffolini T, Sagnelli E, Sagnelli C, Smedile A, Morisco F, Coppola N, Furlan C, Almasio PL. Geographical pattern of chronic liver diseases in Italy: results from two pooled national surveys. Eur J Intern Med. 2019;61(05):40–3.
Sikui H, Xian Z, Xin Y. Investigation on incidence of fatty liver disease in school faculty. Chin J School Doctor. 2011;25(09):710–1.
Yuping L, Youfu C, Hua Y. Three years investigation on morbidity rate of public servants with fatty liver in Sichuan province and analysis of its risk factors. J Sichuan Contin Educ Coll Med Sci. 2008;27(03):188–9+193.
Xingxiang Y, Xiaowei L, Min D, Juhua Z. A epidemiological survey on fatty liver and its risk factors among adult population of health exam ination in Chengdu. Sichuan Med J. 2009;30(06):811–3.
Zhilin Y, Xiaoling L, Ziju F, Tiangui J, Liangming Y, Yejun T, Kun M, Shaofu S, Guihua Z, Tingchao Z, et al. Epidemiological survey on prevalence and risk factors of fatty liver among employees of administrative enterprises and institutions in Guangyuan City, Sichuan Province. Chin J Gastroenterol Hepatol. 2008;17(08):658–61.
Juhua Z. Clinical analysis of fatty liver in healthy Sichuan University in 2007. Pract J Clin Med. 2008;05(03):95.
Bao XY, Xu BB, Fang K, Li Y, Hu YH, Yu GP. Changing trends of hospitalisation of liver cirrhosis in Beijing, China. BMJ Open Gastroenterol. 2015;2(1):1–6.
Huang A, Chang B, Sun Y, Lin H, Li B, Teng G, Zou ZS. Disease spectrum of alcoholic liver disease in Beijing 302 Hospital from 2002 to 2013: a large tertiary referral hospital experience from 7422 patients. Medicine (Baltimore). 2017;96(7):1–5.
Wang H, Gao P, Chen W, Yuan Q, Lv M, Bai S, Wu J. A cross-sectional study of alcohol consumption and alcoholic liver disease in Beijing: based on 74,998 community residents. BMC Public Health. 2022;22(1):723–34.
Bing Z, Hongling L, Linmin L, Yihui R, Hong Z, Wanshu L, Shaoli Y, Shaojie X. Clinical characteristics of 4132 patients with alcoholic liver disease. Chin J Liver Dis. 2015;23(09):680–3.
Shangru C, Zhijie L, Chao Z, Shuhua W, Chun Y, Guanghua L. Epidemiological survey of fatty liver and analysis of risk factors in a general adult population in Xinhui district. Mod Digestion Interv. 2008;13(02):93–6.
Wansheng H, Jing G, Fuming T, Weimei H, Jinghua C. The epidemiology investigation of adult fatty liver in Ronggui and its integrating intervention. Modern Hospitals. 2006;6(10):123–5.
Zhouping K, Liqin H, Jiafeng Z. Prevalence of fatty liver in the old people of Zhongshan. Guangzhou Med J. 2011;42(03):44–5.
Xinsheng L. Epidemiological analysis of fatty liver prevalence and its risk factors in some area of Zhongshan. Modern Hospitals. 2014;14(01):148–9.
Jinxiang M, Yongjian Z, Pingyan C, Yuqiang N, Shengli S, Yuyuan L. Epidemiological survey on fatty liver in rural area of Guangdong province. Chin J Public Health. 2007;23(07):874–6.
Deping S. Etiological analysis of 652 cases of fatty liver. Med J Ind Enterprise. 2003;16(02):2–4.
Ming S, Qing T. Risk factors for fatty liver among Nanjing University staff. Chin J School Health. 2005;26(10):882–3.
Jiangao F, Jun Z, Xinjian L, Rui L, Fei D, Xiaomin S. Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai. Chin J Liver Dis. 2005;13(02):9–14.
Li Q, Qing S, Hongxia G, Shuai L, Weixia J. Epidemiological surve y of prevalence of fatty liver and its risk factors in adult population of Chongming district, Shanghai. J Intern Med Concepts Pract. 2012;7(04):280–3.
Hongxia D, Fengxi D, Li Z, Tongxin Z, Ying T. Investigation of the prevalence of fatty liver in 761 adult patients and analysis of the related risk factors. Chin J Clin Gastroenterol. 2010;22(04):236–9.
Yaxue Z. The association between Alcohol and Fatty Liver in Jinchang Cohort. Master: Lan Zhou University; 2017.
Qiannan L, Jianbo C, Yanxia B, Yan W, Guangrong D. An epidemiological survey of alcoholic liver disease among staff of Yanchang Oilfield. J Clin Hepatol. 2017;33(09):1769–73.
Lina Q. Epidemiological investigation on prevalence and risk factors of fatty liver in adults in Yan'an City. Master: Yan'an University; 2015:1-48.
Xiaolan L, Ming T, Ping Z, Hongli Z, Xiaodong Z, Yan G. Analysisi of dangerous factors for alcoholic liver disease. Chin J Liver Dis. 2004;12(07):63–4.
Lei C, Yang H, Li Z, Xiaoqian Z, Xu Y. Epidemiological investigation of alcoholic liver disease among adults undergoing physical examination in Guiyang. Guizhou Med J. 2010;34(07):645–7.
Xun L, Fengmei L, Min D, Quan L, Ruixia L, Bi Z, Hong Z. Epidemiological study on prevalence rate and risk factors for fatty liver disease in workers in urban Bijie. Prev Treat Cardiovasc Dis. 2012;06(18):7–10.
Ling J, Dongsheng L, Dangping F. Investigation of fatty liver in 2536 healthy people. J Prevent Med Chin People’s Liberation Army. 2008;26(05):377.
Youming L, Weixing C, Zhaohui Y, Min L, Youshi L, Genyun X. An epidemiological survey of alcoholic liver disease in Zhejiang province. Chin J Liver Dis. 2003;11(11):9–11.
Fengqin S, Yun Q. Clinical significance of ultrasonography in the diagnosis of fatty liver. J Baotou Med. 2009;33(04):203–4.
Guoliang Y, Zhaohui Y, Hong S, Junlin W, Wenyu W. Investigation on the prevalence of alcoholic liver disease in Xiangshan fishermen. Zhejiang J Prevent Med. 2005;17(06):15.
Zhongdong Z, Huimin L, Junping S, Guoqiang L. Clinical analysis of the relationship between fatty liver and chronic hepatitis B. Chin J Med. 2009;44(02):41–2.
Minxia P, Yekai W, Xiaojuan Z, Guoqiang Z. Epidemiological survey of prevalence of fatty liver and its risk factors in male fishmen of Zhoushan City. Chin J Health Lab Technol. 2011;21(05):1275–7+1279.
Yunfei Z, Weijun C. Epidemiological investigation of alcoholic fatty liver. J Mod Med Health. 2001;17(09):732–3.
Jia W, Quanfeng W, Xuefei Y. Analysis of the occuational physical examination on B-Ultrasonic fatty liver in Zhongyuan petroleum chemical company. Occup Health. 2008;24(05):423–4.
Shengqi W, Junjie W, Jing W. Investigation on the prevalence of alcoholic liver disease among outbound personnel at Henan port. Port Health Control. 2003;08(04):12–3.
Shunling H, Shuiqi D, Xuehong Z, Youjun Y, Meilian T, Changgeng Y. Epidemiological survey of alcoholic liver disease in Hunan province. J Chin Physician. 2005;07(03):426–7.
Longju Y, Xuyun M, Jianwei G, Lijian Z. Study on the related factors of fatty liver. J Chin Physician. 2003;05(01):92–3.
Zhiyou C, Zexin S. Study on fatty liver and its related factors. J Jilin Mil Med Coll Fourth Mil Med Univ. 2001;23(01):40.
Jie S. The status of epidemiological investigation and analysis of relevant factors about drinking and alcoholic liver disease in Dehui city. Doctor: Jilin University; 2008.
Shilin C, Xiaodan M, Bingyuan W, Aiqing X. An epidemiologic survey of alcoholic liver disease in some cities of Liaoning Province. J Pract Hepatol. 2010;13(06):428–35.
Xiaodong S, Qi W, Shumei H, Yuchun T, Jie S, Junqi N. Epidemiology and analysis on risk factors of non-infectious chronic diseases in adults in northeast China. J Jilin Univ. 2011;37(02):379–84.
Jinglian W, Linyan F, Xueyan Q. Prevalence of alcoholic liver disease in some Daur residents. Chin J Gen Pract. 2003;02(01):55–6.
Hsieh PH, Huang JY, Nfor ON, Lung CC, Ho CC, Liaw YP. Association of type 2 diabetes with liver cirrhosis: a nationwide cohort study. Oncotarget. 2017;8(46):81321–8.
Baima-Kangzhuo, Ouzhu-Luobu, Ciren-Yangzong, Luobu-Zhandui, La Y, Qiangba-Danzeng, Chaoying C, Ciren-Yangjin, Zeng D. Prevalence and risk factors of alcoholic liver disease among Tibetan native adults in Lhasa. Chin J Public Health 2016, 32(03):295-298.
Qiuyue Y, Lijuan Z, Peng X, Ji L, Hailong Z, Jingwei L. Analysis of related factors of alcoholic liver disease in jinzhou area. Chin J Misdiagn. 2011;11(28):6834.
Yaping W. Ultrasonic diagnosis of fatty liver and alcoholic liver. Chin J Ethnomed Ethnopharmacy. 2012;21(07):79.
Jinhui Y, Qiudong Z, Pengfen X, Dongmei H. Investigation of alcoholic liver disease in ethnic groups of Yuanjiang county in Yunnan. Chin J Gastroenterol Hepatol. 2011;20(12):1137–9.
Huang C, Lv XW, Xu T, Ni MM, Xia JL, Cai SP, Zhou Q, Li X, Yang Y, Zhang L, et al. Alcohol use in Hefei in relation to alcoholic liver disease: a multivariate logistic regression analysis. Alcohol. 2018;71(01):1–4.
Wenyu H. Clinical significance of ultrasonography in the diagnosis of fatty liver. Chin J Gen Pract. 2011;9(09):1464–5.
Wang H, Ma L, Yin Q, Zhang X, Zhang C. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China. Alcohol Clin Exp Res. 2014;38(4):1035–41.
Xiaohua Y. Comparison of serum indicators of people with alcoholic fatty liver and nonalcoholic fatty liver. J Shandong Med Coll. 2010;32(03):175–8.
Tiemin L, Guochen Z. Discussion on fatty liver and its related pathogenic factors in civil servants. Occup Health. 2001;17(09):29–30.
Ying X, Jiong R, Jun Z. Epidemiological Survey of Prevalence of Fatty Liver and Risk Factors in the Uyghur and Han Nationality Patients of Shuimogou District. Xinjiang Med J. 2011;41(11):13–5+19.
Hua Y, Fenli Z, Yanqiong G, Xiaolan L, Jinyan L. Epidemiological study on alcohol consumption and alcoholic liver disease. Shaanxi Med J. 2015;44(07):917–8+920.
Hua Y, Xiaolan L, Jinyan L, Xiaoyan Z. Epidemiological analysis of alcoholic and non-alcoholic fatty liver in Shanxi and Gansu province. Chin J Gastroenterol Hepatol. 2007;16(04):347–50+353.
Sy AM, Ching R, Olivares G, Vinas C, Chang R, Bergasa NV. Hispanic ethnicity is associated with increased morbidity and mortality in patients with alcoholic liver disease. Ann Hepatol. 2017;16(1):169–71.
Hourigan KJ, Bowling FG. Alcoholic liver disease: a clinical series in an Australian private practice. J Gastroenterol Hepatol. 2001;16(10):1138–43.
Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol. 2006;101(7):1500–8.
Barritt AST, Jiang Y, Schmidt M, Hayashi PH, Bataller R. Charges for alcoholic cirrhosis exceed all other etiologies of cirrhosis combined: a national and state inpatient survey analysis. Dig Dis Sci. 2019;64(6):1460–9.
Pinon-Gutierrez R, Durbin-Johnson B, Halsted CH, Medici V. Clinical features of alcoholic hepatitis in latinos and caucasians: a single center experience. World J Gastroenterol. 2017;23(40):7274–82.
Fong TL, Kanel GC, Conrad A, Valinluck B, Charboneau F, Adkins RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology (Baltimore, MD). 1994;19(3):554–7.
Jinjuvadia R, Jinjuvadia C, Puangsricharoen P, Chalasani N, Crabb DW, Liangpunsakul S, Translational R. Evolving alcoholic hepatitis treatment C: concomitant psychiatric and nonalcohol-related substance use disorders among hospitalized patients with alcoholic liver disease in the United States. Alcohol Clin Exp Res. 2018;42(2):397–402.
Fan X, McCullough RL, Huang E, Bellar A, Kim A, Poulsen KL, McClain CJ, Mitchell M, McCullough AJ, Radaeva S, et al. Diagnostic and prognostic significance of complement in patients with alcohol-associated hepatitis. Hepatology (Baltimore, MD). 2021;73(3):983–97.
Douds AC, Cox MA, Iqbal TH, Cooper BT. Ethnic differences in cirrhosis of the liver in a British city: alcoholic cirrhosis in South Asian men. Alcohol Alcohol. 2003;38(2):148–50.
Levy R, Catana AM, Durbin-Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res. 2015;39(3):566–74.
Rajbhandari R, Danford CJ, Chung RT, Ananthakrishnan AN. HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. Aliment Pharmacol Ther. 2015;41(10):928–38.
Waleed M, Abdallah MA, Kuo YF, Arab JP, Wong R, Singal AK. Higher frequency of hospital-acquired infections but similar in-hospital mortality among admissions with alcoholic hepatitis at academic vs. Non-academic Centers. Front Physiol. 2020;11(06):1–9.
Mills PR, MacSween RN, Dick HM, Hislop WS. Histocompatibility antigens in patients with alcoholic liver disease in Scotland and northeastern England: failure to show an association. Gut. 1988;29(2):146–8.
Heslin KC, Elixhauser A, Steiner CA. Identifying in-patient costs attributable to the clinical sequelae and comorbidities of alcoholic liver disease in a national hospital database. Addiction (Abingdon, England). 2017;112(5):782–91.
Singal AK, Sagi S, Kuo YF, Weinman S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. Eur J Gastroenterol Hepatol. 2011;23(3):204–9.
Ladhani S, Hirode G, Singal AK, Wong RJ. Impact of safety-net burden on in-hospital mortality and hospitalization costs among patients with alcoholic hepatitis and alcoholic cirrhosis. Alcohol Alcohol. 2021;56(3):368–75.
Nahon P, Nuraldeen R, Rufat P, Sutton A, Trautwein C, Strnad P. In alcoholic cirrhosis, low-serum hepcidin levels associate with poor long-term survival. Liver Int. 2016;36(2):185–8.
Lamm K, McCarter M, Russo MW. Is there a futility discriminant function score for alcoholic hepatitis? J Clin Med. 2021;10(13):1–8.
Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol. 2005;42(5):700–6.
Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrie N, Beaugrand M, Charnaux N, Trinchet JC, et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol. 2013;58(2):312–8.
Fan X, Huang X, Hershman M, Zheng X, Jiang C, Yue B, Weisberg I. Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. Eur J Gastroenterol Hepatol. 2020;32(9):1160–7.
Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Am J Med. 1984;76(2):211–22.
Lowenfels AB, Maisonneuve P, Grover H, Gerber E, Korsten MA, Antunes MT, Marques A, Pitchumoni CS. Racial factors and the risk of chronic pancreatitis. Am J Gastroenterol. 1999;94(3):790–4.
Beaudoin JJ, Liang T, Tang Q, Banini BA, Shah VH, Sanyal AJ, Chalasani NP, Gawrieh S. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. Alcohol Clin Exp Res. 2021;45(4):709–19.
Makar M, Reja D, Chouthai A, Kabaria S, Patel AV. The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA. Eur J Gastroenterol Hepatol. 2021;33(6):905–10.
May FP, Rolston VS, Tapper EB, Lakshmanan A, Saab S, Sundaram V. The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. BMC Gastroenterol. 2016;16(1):129.
Nasir M, Vinsard DG, Wakefield D, Karagozian R. The important role of immunization in alcoholic and non-alcoholic chronic liver disease: a population-based study. J Dig Dis. 2020;21(10):583–92.
Lee EY, Xuan Mai TT, Chang Y, Ki M. Trends of liver cancer and its major risk factors in Korea. Epidemiol Health. 2015;37(06):e2015016.
Israelsen M, Misas MG, Koutsoumourakis A, Hall A, Covelli C, Buzzetti E, Prat LI, Roccarina D, Luong TV, Quaglia A, et al. Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. Dig Liver Dis. 2022;54(5):663–8.
Arab JP, Diaz LA, Baeza N, Idalsoaga F, Fuentes-Lopez E, Arnold J, Ramirez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study. J Hepatol. 2021;75(5):1026–33.
Sullivan MK, Daher HB, Rockey DC. Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis. Am J Med Sci. 2022;363(6):484–9.
Morales-Arraez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: a global study. Am J Gastroenterol. 2022;117(2):301–10.
Laswi H, Abusalim AR, Warraich MS, Khoshbin K, Shaka H. Trends and outcomes of alcoholic liver cirrhosis hospitalizations in the last two decades: analysis of the nationwide inpatient sample. Gastroenterology Res. 2022;15(2):91–9.
Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol. 2010;44(4):301–7.
Fengyi L, Yong’an Y, Jinhui S, Daoming Z, Xianjun Z. Distribution research on the clinical data of 199 cases with alcoholic fibrosis. Chin Arch Tradit Chin Med. 2009;27(06):1250–3.
Guonv Z, Xiangjiu H. Diagnostic value of B-ultrasound in alcoholic liver disease. J Med Sci YanBian Univ. 1991;03:206–7.
Liyan L. Genetic polymorphism and mRNA levels of CYP1A1 and PPRAα in alcoholic liver disease. Doctor: Jilin Universisty; 2011.
Ying L. Genetic polymorphism and mRNA levels of CYP450IIE1 and GSTP1 in alcoholic liver disease. Doctor: Jilin University; 2009.
Yang Y, Yanan H. Clinical value of ultrasonography in the diagnosis of alcoholic liver disease. Clin Focus. 2012;27(17):1537–9.
Jianqiang H, Jun C, Yan T. Relevant factors and clinical treatment of aIcoholic liver disease between Li minority and Han people. J Hainan Med Univ. 2011;17(09):1175–8.
Li L, Anxin Z, Fuhe C. Clinical analysis of 64 cases of alcoholic liver diseases. J Mod Med Health. 2008;24(10):1484–5.
Yonghui Q. Clinical characteristics of 62 patients with alcoholic liver disease. China Trop Med. 2014;14(05):639–40.
Ruiqiao Y, Xinhua Z, Xuemei T, Cuiying G, Li S, Jianguo W, Xiaoyan M, Ziman N, Jitan S, Bingyuan W. Investigation on the relationship between alcohol consumption and alcoholic fatty liver among ethnic minorities in Xinjiang. Chin J Liver Dis. 2005;13(11):63–5.
Keqin S, Houdong L, Li J. Clinicopathological observation of alcoholic liver disease in Tibetan people at high altitude. Tibet Sci Technol. 2000;06:11–3.
Maoqiang L. Clinical analysis of 62 cases of alcoholic liver diseases. Med Inform. 2010;23(08):2649.
Anqin C. Clinical analysis of 76 cases of alcoholic liver disease. For all Health. 2013;7(20):158.
Zhaowen L, Wenheng H, Minggu Z. Study on the risk factors influencing the prognosis of alcoholic liver disease. Inner Mongolia Med J. 2018;50(11):1337–8.
Dou W, Ying Y, Yingqian D. Epidemiological study on alcoholic liver disease in Xigaze area. World Latest Med. 2018;18(78):210–1+217.
Xiaolan L, Miyan T, Yan G, Ping Z, Hongli Z. Epidemiology of alcoholic liver diseases in Xi’an. World Chin J Dig. 2003;11(06):719–22.
Min S, Chunying L. Clinical analysis of 112 cases of alcoholic liver diseases. J Zhangjiakou Med Coll. 2004;21(01):64–5.
Xie Y-D, Feng B, Gao Y, Wei L. Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis. Hepatobiliary Pancreat Dis Int. 2013;12(6):594–601.
Arun AC, Ilangovan N, Rajma J. Risk factors for alcohol use relapse after abstinence in patients with alcoholic liver disease. J Fam Med Prim Care. 2020;9(12):5995–9.
Cichoz-Lach H, Partycka J, Nesina I, Celinski K, Slomka M, Wojcierowski J. Alcohol dehydrogenase and aldehyde dehydrogenase gene polymorphism in alcohol liver cirrhosis and alcohol chronic pancreatitis among Polish individuals. Scand J Gastroenterol. 2007;42(4):493–8.
Faizallah R, Woodrow JC, Krasner NK, Walker RJ, Morris AI. Are HLA antigens important in the development of alcohol-induced liver disease? Br Med J (Clin Res Ed). 1982;285(6341):533–4.
Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH, Kim CY. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci. 2001;16(6):745–50.
Kwon SY, Ahn MS, Chang HJ. Clinical significance of hepatitis C virus infection to alcoholics with cirrhosis in Korea. J Gastroenterol Hepatol. 2000;15(11):1282–6.
Vaz K, Little R, Majeed A, Kemp W, Roberts SK. Determinants of short- and long-term outcomes of an Australian cohort of patients admitted with alcoholic hepatitis. Dig Dis Sci. 2022;67(7):3356–65.
Serra MA, Escudero A, Rodriguez F, del Olmo JA, Rodrigo JM. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol. 2003;36(2):170–4.
Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trinchet JC, Dalsoglio D, Prevot S, Naveau S. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25(9):1047–54.
Tan JH, Jin YC, Cao RC, Zhou L, Zhang GW. Risk factors for the concomitant occurrence of alcoholic chronic pancreatitis and alcoholic liver cirrhosis: a 10-years cohort study at a tertiary hospital in China. Eur J Gastroenterol Hepatol. 2020;32(9):1229–34.
Bhattacharyya M, Barman NN, Goswami B. Survey of alcohol-related cirrhosis at a tertiary care center in North East India. Indian J Gastroenterol. 2016;35(3):167–72.
Vijayakumar S, Viswanathan S, Jain D. Utility of platelet indices in alcoholic hepatitis: a retrospective study. Porto Biomed J. 2020;5(5):e082-089.
Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology (Baltimore, MD). 2002;35(3):635–8.
Wei DM, Jiao HB, Liu YT, Zhao J, Hanbai BYL, Tong J, Wang BY. Clinical diagnosis of alcoholic hepatitis in Tongliao City, Inner Mongolia. Chin J Hepatol. 2021;29(9):861–6.
Chang L, Ying W, Bingyuan W, Bing C, Xiaohu H, Guoqing X, Xiaodan M. Clinical characteristics and curative effect analysis of 88 patients with alcoholic hepatitis. Drug Eval. 2007;4(02):110–3.
Chao G. Association between PNPLA3 gene polymorphism and genetic susceptibility to alcoholic liver disease. Master: Shanxi Medical University; 2014.
Lixia W. Clinical analysis of 164 patients with alcoholic liver disease. Master: Dalian Medical University; 2004.
Caiyan Z, Yadong W, Pingping Z. Analysis on clinical features of fatty liver disease and its risk factors. Clinical Focus. 2008;23(04):247–51.
Allen JP, Litten RZ. Recommendations on use of biomarkers in alcoholism treatment trials. Alcohol Clin Exp Res. 2003;27(10):1667–70.
Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, Rueff B, Valla DC, Degos F. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (Baltimore, MD). 2001;34(1):121–5.
Jinzhong Z, Xiuzhi Z, Ningning L, Yanfei L, Xiaoli L, Chunyan K, Jie C. Analysis of the effects of smoking and drinking on alcoholic fatty liver disease. J Henan Med Coll. 2018;30(04):327–30.
Otete HE, Orton E, Fleming KM, West J. Alcohol-attributable healthcare attendances up to 10 years prior to diagnosis of alcoholic cirrhosis: a population based case-control study. Liver Int. 2016;36(4):538–46.
Spicak J, Pulkertova A, Kralova-Lesna I, Suchanek P, Vitaskova M, Adamkova V. Alcoholic chronic pancreatitis and liver cirrhosis: coincidence and differences in lifestyle. Pancreatology. 2012;12(4):311–6.
Pradhan B, Hadengue A, Chappuis F, Chaudhary S, Baral D, Gache P, Karki P, Rijal S. Alcoholic liver disease in Nepal: identifying homemade alcohol as a culprit. Clin Exp Gastroenterol. 2015;2015(08):183–9.
Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11(1):95–101.
Poynard T, Abella A, Pignon JP, Naveau S, Leluc R, Chaput JC. Apolipoprotein AI and alcoholic liver disease. Hepatology (Baltimore, MD). 1986;6(6):1391–5.
Zeng D, Huang Q, Yu Z, Wu H. Association between aldehyde dehydrogenase 2 gene rs671 G>A polymorphism and alcoholic liver cirrhosis in southern Chinese Hakka population. J Clin Lab Anal. 2021;35(7):e23855.
Ratib S, Fleming KM, Crooks CJ, Walker AJ, West J. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol. 2015;110(8):1149–58.
Ganne-Carrie N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69(6):1274–83.
Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, Rosendahl J, et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology (Baltimore, MD). 2020;72(1):88–102.
Otete H, Deleuran T, Fleming KM, Card T, Aithal GP, Jepsen P, West J. Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data. J Hepatol. 2018;69(3):697–704.
Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, Lollivier J, Lemaitre E, Dharancy S, Lassailly G, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology (Baltimore, MD). 2017;66(5):1464–73.
Adejumo AC, Cholankeril G, Iqbal U, Yoo ER, Boursiquot BC, Concepcion WC, Kim D, Ahmed A. Readmission rates and associated outcomes for alcoholic hepatitis: a nationwide cohort study. Dig Dis Sci. 2020;65(4):990–1002.
Pathak OK, Paudel R, Panta OB, Pant HP, Giri BR, Adhikari B. Retrospective study of the clinical profile and prognostic indicators in patients of alcoholic liver disease admitted to a tertiary care teaching hospital in Western Nepal. Saudi J Gastroenterol. 2009;15(3):171–5.
Wang X, Lin SX, Tao J, Wei XQ, Liu YT, Chen YM, Wu B. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014;20(37):13546–55.
Bjornsson ES, Hauksson K, Sigurdardottir R, Arnardottir M, Agustsson AS, Lund SH, Kalaitzakis E. Abstinence from alcohol and alcohol rehabilitation therapy in alcoholic liver disease: a population-based study. Scand J Gastroenterol. 2020;55(4):472–8.
Silva João M, Silva Mário J, Calinas F, Nogueira Paulo J. Burden of Liver Cirrhosis in Portugal between 2010 and 2017. GE Port J Gastroenterol. 2021;28(3):153–61.
Tanaka T, Yabusako T, Yamashita T, Kondo K, Nishiguchi S, Kuroki T, Monna T. Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res. 2000;24(4 Suppl):112S-116S.
Gonçalves PL, da Penha Z-G, Marques CC, Mendonça AT, Gonçalves CS, Pereira FEL. Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espírito Santo. Clinics. 2013;68(3):291–5.
Thuluvath PJ, Ahn E, Nguyen GC. Hepatitis C as a prognostic indicator among noncirrhotic patients hospitalized with alcoholic hepatitis. Can J Gastroenterol. 2013;27(11):639–42.
Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population-based study. J Hepatol. 2008;49(5):732–8.
Appel-da-Silva MC, Miozzo SA, Dossin IA, Tovo CV, Branco F, de Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol. 2016;22(46):10219–25.
Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330–9.
Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(2):168–74.
Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjodleifsson B, Bjornsson E. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol. 2009;44(8):984–93.
Kim WR, Gross JB Jr, Poterucha JJ, Locke GR 3rd, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology (Baltimore, MD). 2001;33(1):201–6.
Fernandes SR, Marques da Costa P, Vitor S, Carvalho JR, Santos P, Moura CM, Cortez-Pinto H, Ramalho F, Velosa J. Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis. Eur J Gastroenterol Hepatol. 2017;29(10):1141–8.
Jeong JY, Lim S, Sohn JH, Lee JG, Jun DW, Kim Y. Presence of sarcopenia and its rate of change are independently associated with long-term mortality in patients with liver cirrhosis. J Korean Med Sci. 2018;33(50):1–13.
Tsutsumi M, Ishizaki M, Takada A. Relative risk for the development of hepatocellular carcinoma in alcoholic patients with cirrhosis: a multiple logistic-regression coefficient analysis. Alcohol Clin Exp Res. 1996;20(4):758–62.
N’Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006;4(8):1062–8.
Huang HH, Lin HH, Shih YL, Chen PJ, Chang WK, Chu HC, Chao YC, Hsieh TY. Spontaneous intracranial hemorrhage in cirrhotic patients. Clin Neurol Neurosurg. 2008;110(3):253–8.
Silva MJ, Rosa MV, Nogueira PJ, Calinas F. Ten years of hospital admissions for liver cirrhosis in Portugal. Eur J Gastroenterol Hepatol. 2015;27(11):1320–6.
Said A, Williams J, Holden J, Remington P, Musat A, Lucey M. The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting. Clin Gastroenterol Hepatol. 2004;2(10):928–34.
Serste T, Cornillie A, Njimi H, Pavesi M, Arroyo V, Putignano A, Weichselbaum L, Deltenre P, Degre D, Trepo E, et al. The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis. J Hepatol. 2018;69(2):318–24.
Armstrong PR, Ring E, MacNicholas R. A decade of rising alcoholic liver disease hospital admissions and deaths in Irish hospitals, 2007–2016: a retrospective cross-sectional analysis. Eur J Gastroenterol Hepatol. 2022;34(6):671–7.
Tailakh MA, Poupko L, Kayyal N, Alsana A, Estis-Deaton A, Etzion O, Fich A, Yardni D, Abu-Freha N. Liver cirrhosis, etiology and clinical characteristics disparities among minority population. J Immigr Minor Health. 2022;24(5):1122–8.
Daoming Z, Yuanxin W, Jingbo Z, Tailing W, Lan Z, Kelun Z. Clinical analysis of 124 cases of alcoholic liver disease. Chin J Liver Dis. 1995;11(04):224.
Cuijuan Z, Hui J. Detection and analysis of hepatitis virus in 150 patients with alcoholic liver disease. J Med Inform. 2010;23(06):1999.
Yiqiang Z. Clinical analysis of 70 cases of alcoholic liver disease. Chin Pract Med. 2009;4(19):88–9.
Changyan C. Clinical characteristics and therapeutic effect of 76 cases of alcoholic liver disease. China Clin Pract Med. 2008;2(12):56–7.
Ming Z. Etiological analysis of liver cirrhosis of 824cases. Chongqing medicien. 2006;35(5):438–41.
Liang L, Chuntao L, Hui Z. Clinical diagnosis and treatment of 89 cases of alcoholic liver disease. Guide China Med. 2012;10(25):141–2.
Shaopeng K, Wanchao L, Zhijun S, Qi L, Yongnian L, Meiyu S. Clinical analysis of 168 cases of alcoholic liver diseases. Chin J Integr Tradit West Med Liver Dis. 1999;09(S1):77–9.
Baochun Y. Clinical analysis of 58 cases of alcoholic liver diseases. Anthology Med. 2005;24(05):727–9.
Mengshan J. Clinical diagnosis and treatment of 70 cases of alcoholic liver disease. Chin Med Herald. 2009;6(25):154.
Chunhua L. Clinical analysis of 78 cases of alcoholic liver diseases. Guide China Med. 2011;9(32):66–7.
Hairu H. Clinical diagnosis and treatment of 85 cases of alcoholic liver disease. China Pract Med. 2009;4(20):123–4.
Haiying Y, Yun L. Causes and nursing care of patients with alcoholic liver disease who continue to drink. J Mod Med Health. 2009;25(17):2649–50.
Houji T, Yaonan Z, Chunlei L. Clinical observation of alcoholic liver disease. J Youjiang Med Univ Nationalities. 2006;01(06):963–4.
Yu M. Analysis of clinical characteristics and prognosis of alcoholic liver disease. China Pract Med. 2012;7(05):112–3.
Yu T, Ye H, XiaoJuan W. Analysis of related factors influencing alcoholic liver disease. China Pract Med. 2011;6(25):98–9.
Nan J. Investigation on the factors influencing alcoholic liver disease. Securities Futures China. 2011;2011(03):128.
Jianan H. Analysis of the related factors affecting alcoholic liver disease. J Youjiang Med Univ Nationalities. 2008;01(01):42–3.
Chuanfeng L, Xiang Q, Yunfeng P. Clinical analysis of 146 cases of alcoholic liver diseases. Chin J Clini Hepatol. 2004;20(03):157–8.
Yue Z, Jiangao F, Zhengli Y. Clinical analysis of 59 cases of alcoholic liver diseases. Chin Hepatol. 2003;08(02):62–3.
Morgan MY, Sharma M, Atkinson SR. Genetic and Environmental Susceptibility to Alcoholic Hepatitis. Clin Liver Dis. 2021;25(3):517–35.
Zhidong L. Analysis of ultrasonography in 132 cases of alcoholic liver disease. Guide Chin Med. 2012;10(36):491–2.
Maocong Y, Yang L, Zhen X, Xiuzhen Y. Clinical features of patients with alcoholic liver disease: an analysis of 155 cases. J Pract Hepatol. 2017;20(01):60–4.
Nalpas B, Hispard E, Thépot V, Pot S, Dally S, Berthelot P. A comparative study between carbohydrate-deficient transferrin and gamma-glutamyltransferase for the diagnosis of excessive drinking in a liver unit. J Hepatol. 1997;27(6):1003–8.
Sujan R, Cruz-Lemini M, Altamirano J, Simonetto DA, Maiwall R, Axley P, Richardson T, Desai V, Cabezas J, Vargas V, et al. A validated score predicts acute kidney injury and survival in patients with alcoholic hepatitis. Liver Transpl. 2018;24(12):1655–64.
Hamlyn AN. Alcoholic liver disease in women. Br Med J. 1977;1(6068):1085–6.
Alves PS, Correia JP, Borda d’ Agua C, Portugal L, Capaz V, Rodrigues ML, Rodrigues HL. Alcoholic liver diseases in Portugal Clinical and laboratory picture, mortality, and survival. Alcohol Clin Exp Res. 1982;6(2):216–24.
Ravi S, Bade KS, Hasanin M, Singal AK. Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis. Gastroenterol Rep (Oxf). 2017;5(3):232–6.
Goyal SK, Dixit VK, Jain AK, Mohapatra PK, Ghosh JK. Assessment of the Model for End-stage Liver Disease (MELD) Score in Predicting Prognosis of Patients with Alcoholic Hepatitis. J Clin Exp Hepatol. 2014;4(1):19–24.
Gluud C, Tage-Jensen U. Autoantibodies and immunoglobulins in alcoholic steatosis and cirrhosis. Acta Med Scand. 1983;214(1):61–6.
Sahlman P, Nissinen M, Pukkala E, Farkkila M. Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996–2013. Int J Cancer. 2016;138(11):2616–21.
Krasner N, Davis M, Portmann B, Williams R. Changing pattern of alcoholic liver disease in Great Britain: relation to sex and signs of autoimmunity. Br Med J. 1977;1(6075):1497–500.
Deleuran T, Gronbaek H, Vilstrup H, Jepsen P. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther. 2012;35(11):1336–42.
Potter JF, James OF. Clinical features and prognosis of alcoholic liver disease in respect of advancing age. Gerontology. 1987;33(6):380–7.
Ray S, Khanra D, Sonthalia N, Kundu S, Biswas K, Talukdar A, Saha M, Bera H. Clinico-biochemical correlation to histological findings in alcoholic liver disease: a single centre study from eastern India. J Clin Diagn Res. 2014;8(10):MC01-05.
Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology (Baltimore, MD). 1997;25(1):108–11.
Chang C, Wang TJ, Chen MJ, Liang SY, Wu SF, Bai MJ. Factors influencing readiness to change in patients with alcoholic liver disease: a cross-sectional study. J Psychiatr Ment Health Nurs. 2020;28(3):344–55.
Sagnelli E, Stroffolini T, Sagnelli C, Pirisi M, Babudieri S, Colloredo G, Russello M, Coppola N, Gaeta GB, Cacopardo B, et al. Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. Infection. 2018;46(1):93–101.
Pares A, Barrera JM, Caballeria J, Ercilla G, Bruguera M, Caballeria L, Castillo R, Rodes J. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (Baltimore, MD). 1990;12(6):1295–9.
Guilera M, Saiz JC, Lopez-Labrador FX, Olmedo E, Ampurdanes S, Forns X, Bruix J, Pares A, Sanchez-Tapias JM, Jimenez de Anta MT, et al. Hepatitis G virus infection in chronic liver disease. Gut. 1998;42(1):107–11.